Jpmorgan Chase & CO Tyra Biosciences, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 364,751 shares of TYRA stock, worth $8.51 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

364,751

Previous 380,597 4.16%

Holding current value

$8.51 Million

Previous $6.24 Million 6.55%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$14.45 - $20.22 $228,974 - $320,406	-15,846 Reduced 4.16%	364,751 $5.83 Million
Q1 2024 May 10, 2024	SELL	$11.61 - $20.0 $245,075 - $422,180	-21,109 Reduced 5.25%	380,597 $6.24 Million
Q4 2023 Feb 12, 2024	BUY	$11.01 - $14.95 $45,008 - $61,115	4,088 Added 1.03%	401,706 $5.56 Million
Q3 2023 Nov 14, 2023	SELL	$13.15 - $16.08 $339,309 - $414,912	-25,803 Reduced 6.09%	397,618 $5.48 Million
Q2 2023 Aug 11, 2023	BUY	$11.99 - $17.51 $2.77 Million - $4.04 Million	230,912 Added 119.95%	423,421 $7.21 Million
Q1 2023 May 18, 2023	BUY	$6.85 - $16.22 $69,589 - $164,778	10,159 Added 5.57%	192,509 $3.09 Million
Q1 2023 May 11, 2023	SELL	$6.85 - $16.22 $115,470 - $273,420	-16,857 Reduced 8.46%	182,350 $2.93 Million
Q4 2022 Feb 13, 2023	SELL	$5.68 - $8.81 $115,531 - $179,195	-20,340 Reduced 9.26%	199,207 $1.51 Million
Q3 2022 Nov 14, 2022	SELL	$6.61 - $12.42 $32,686 - $61,416	-4,945 Reduced 2.2%	219,547 $1.93 Million
Q2 2022 Aug 11, 2022	SELL	$5.26 - $11.19 $20,987 - $44,648	-3,990 Reduced 1.75%	224,492 $1.61 Million
Q1 2022 May 11, 2022	BUY	$10.03 - $14.09 $741,247 - $1.04 Million	73,903 Added 47.81%	228,482 $2.45 Million
Q4 2021 Feb 10, 2022	BUY	$12.23 - $31.35 $1.89 Million - $4.85 Million	154,579 New	154,579 $2.18 Million

Others Institutions Holding TYRA

# of Institutions

Shares Held

43.4M

Call Options Held

Put Options Held

View Full List

About Tyra Biosciences, Inc.

Ticker TYRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,973,600
Market Cap $980M
Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...

More about TYRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Tyra Biosciences, Inc. Transaction History